Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn

Roberts, Jesse D.; Fineman, Jeffrey R.; Morin, Frederick C.; Shaul, Philip W.; Rimar, Stephen; Schreiber, Michael D.; Polin, Richard A.; Zwass, Maurice S.; Zayek, Michael; Gross, Ian; Heymann, Michaël; Zapol, Warren M.; Thusu, Kajori G.; Zellers, Thomas M.; Wylam, Mark E.; Zaslavsky, Alan M.

doi:10.1056/nejm199702273360902

Cited by 802 publications

(409 citation statements)

References 17 publications

Supporting

Mentioning

379

Contrasting

Unclassified

Order By: Relevance

“…Because RCTs have shown that iNO reduced the need for rescue therapy with ECMO in many newborns with PPHN, 206,242,243 iNO was considered a promising therapy for the treatment of acute PH in CDH. 244 Early reports demonstrated that iNO can improve oxygenation and PH in some infants with severe CDH shortly after birth.…”

Section: Pah-specific Therapymentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

Self Cite

948

405

View full text Add to dashboard Cite

Abstract-Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of consensus guidelines from experts in the field. In a joint effort from the American Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. Key Words: AHA Scientific Statements ◼ bronchopulmonary dysplasia ◼ congenital diaphragmatic hernia ◼ congenital heart disease ◼ genetics ◼ persistent pulmonary hypertension of the newborn ◼ sickle cell disease © 2015 by the American Heart Association, Inc., and the American Thoracic Society.Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000329 †Deceased. The American Heart Association and the American Thoracic Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This document was approved by the American Heart Association Science Advisory and Coordinating Committee on May 12, 2015, the American Heart Association Executive Committee on July 22, 2015, and the American Thoracic Society on July 24, 2015.The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000329/-/DC1. The American Heart Association requests that this document be cited as follows: Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037-2099 Copies: This document is available on the World Wide Web site of the American Heart Associat...

show abstract

Section: Pah-specific Therapymentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

Self Cite

948

405

View full text Add to dashboard Cite

show abstract

“…This effect of endogenous NO in the human respiratory tract, derived from the upper airways, was termed ‘aerocrine’ to illustrate the airborne transport of a biological messenger [39]. Since it is known that exogenous NO gas delivered to inhaled air dilates vessels in the lung, leading to increased oxygen uptake and a reduction in pulmonary vascular resistance [46], the vasodilating effect of NO is used for the treatment of pulmonary hypertension [40,47]. …”

Section: Function Of Nomentioning

confidence: 99%

Nitric Oxide: A Promising Methodological Approach in Airway Diseases

Şahin

Klimek

Mullol

et al. 2011

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Nitric oxide (NO) is a potent biological mediator, and has a regulatory role in a wide variety of cellular and tissue functions. In the upper and lower airways, NO has been suggested to be involved in different functions with regulatory, protective, defensive or damaging effects. It is obvious that NO plays an important role in host defense, and is liberated in the nose and the paranasal sinuses. This review aims to highlight some aspects of the origin and function of NO in airway diseases, such as allergic rhinitis, chronic rhinosinusitis with and without nasal polyps, primary ciliary dyskinesia, and cystic fibrosis. In conclusion, NO measurement may be a promising noninvasive diagnostic marker for airway pathologies.

show abstract

“…INO has been used in the therapy of several pediatric and adult lung diseases ( [69][70][71] for review). A major established therapeutic use of INO is in pulmonary hypertension of the newborn [69,[72][73][74]. INO has also been shown to reduce pulmonary artery pressures and/or pulmonary vascular resistance in a number of animal models of acute pulmonary injury [75][76][77][78][79][80], making it relevant for patients with ALI/ARDS.…”

Section: Inhaled Nitric Oxide (Ino)-nitricmentioning

confidence: 99%

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Raghavendran¹,

Pryhuber²,

Chess³

et al. 2008

CMC

111

View full text Add to dashboard Cite

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are characterized by rapid-onset respiratory failure following a variety of direct and indirect insults to the parenchyma or vasculature of the lungs. Mortality from ALI/ARDS is substantial, and current therapy primarily emphasizes mechanical ventilation and judicial fluid management plus standard treatment of the initiating insult and any known underlying disease. Current pharmacotherapy for ALI/ARDS is not optimal, and there is a significant need for more effective medicinal chemical agents for use in these severe and lethal lung injury syndromes. To facilitate future chemical-based drug discovery research on new agent development, this paper reviews present pharmacotherapy for ALI/ARDS in the context of biological and biochemical drug activities. The complex lung injury pathophysiology of ALI/ ARDS offers an array of possible targets for drug therapy, including inflammation, cell and tissue injury, vascular dysfunction, surfactant dysfunction, and oxidant injury. Added targets for pharmacotherapy outside the lungs may also be present, since multiorgan or systemic pathology is common in ALI/ARDS. The biological and physiological complexity of ALI/ARDS requires the consideration of combined-agent treatments in addition to single-agent therapies. A number of pharmacologic agents have been studied individually in ALI/ARDS, with limited or minimal success in improving survival. However, many of these agents have complementary biological/biochemical activities with the potential for synergy or additivity in combination therapy as discussed in this article.

show abstract

Inhaled Nitric Oxide and Persistent Pulmonary Hypertension of the Newborn

Abstract: Inhaled nitric oxide improves systemic oxygenation in infants with persistent pulmonary hypertension and may reduce the need for more invasive treatments.

Cited by 802 publications

References 17 publications

Pediatric Pulmonary Hypertension

Pediatric Pulmonary Hypertension

Nitric Oxide: A Promising Methodological Approach in Airway Diseases

Pharmacotherapy of Acute Lung Injury and Acute Respiratory Distress Syndrome

Contact Info

Product

Resources

About